The investigational chemotherapeutic agent eribulin mesylate demonstrated activity in a heavily pretreated population of women with locally advanced or metastatic breast cancer.

LONDON and SAN DIEGO, CA -- Antisoma plc announces that new preclinical data on its anti-nucleolin aptamer drug AS1411 are presented today at the American Association for Cancer Research (AACR) meeting in San Diego, CA. The presentation shows that AS1411